Source link : https://www.newshealth.biz/health-news/mixed-results-for-factor-xa-reversal-agent-in-ich-annexa-i/
The full results of the ANNEXA-I trial have continued to show mixed effects of the factor Xa inhibitor reversal agent, andexanet (Andexxa/Ondexxya, AstraZeneca), in patients with intracerebral hemorrhage who are taking factor Xa inhibitor anticoagulants, with uncertainly as to whether the benefits would outweigh the risks. The trial results, showing better control of hematoma expansion […]
Author : News Health
Publish date : 2024-05-15 21:00:00
Copyright for syndicated content belongs to the linked Source.